In 2019, Medicare expenditures on skin substitute bandages were $250 million, which dramatically escalated to over $10 billion by 2024. The Biden administration sought to implement a new policy in April 2024, focusing on funding bandages meeting high-quality standards for specific ulcers. However, the Trump administration delayed its enactment, leading to proposed changes in payment rates that may jeopardize the financial viability of bandage producers. Current discussions highlight the balance between cost control and ensuring quality treatment for patients.
"If this exceedingly low payment rate were to take effect, companies producing skin substitutes would no longer be able to cover their production costs, and providers would not be able to afford to treat their patients."
"The Trump administration announced that the policy would be delayed until 2026, despite the Biden administration's attempt to introduce regulations for high-quality bandages."
Collection
[
|
...
]